

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/160055/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Melson, Eka, Davitadze, Meri, Mousa, Aya, Teede, Helena, Boivin, Jacky , Thondan, Mala, Chau Thien, Tay and Kempegowda, Punith 2023. A systematic review of models of care for polycystic ovary syndrome highlights a gap in the literature, especially in developing countries. *Frontiers in Endocrinology* file

Publishers page:

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **A systematic review of models of care for polycystic ovary syndrome**
2 **highlights a gap in the literature, especially in developing countries.**

3 **Eka Melson MSc^{1†}, Meri Davitadze[†] MD²⁺, Aya Mousa PhD³, PCOS SEva working group⁴,**
4 **Helena Teede PhD³, Jacky Boivin PhD⁵, Mala Thondan MD⁶, Chau Thien Tay PhD^{3††}, Punith**
5 **Kempegowda PhD^{4,7††}**

6 ¹University of Leicester, Leicester, United Kingdom

7 ²Clinic NeoLab, Tbilisi, Georgia

8 ³Monash Centre for Health Research and Implementation, Monash University, Melbourne, Australia

9 ⁴Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom

10 ⁵School of Psychology, Cardiff University, Cardiff, Wales, United Kingdom

11 ⁶Harp Family Medical Centre, Melbourne, Australia

12 ⁷Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham,
13 United Kingdom

14 † These authors share first authorship

15 †† These authors share senior authorship

16

17 ***Correspondence:**

18 Dr Punith Kempegowda (ORCHID: 0000-0003-0954-6512)

19 Institute of Applied Health Research, University of Birmingham,

20 Birmingham, United Kingdom

21 Email: p.kempegowda@bham.ac.uk

22 **Keywords: Polycystic ovary syndrome, PCOS, model of care, multidisciplinary care, quality of**
23 **life.**

24

25 Abstract

26 **Introduction:** To identify available polycystic ovary syndrome (PCOS) models of care (MoC) and
27 describe their characteristics and alignment with the international PCOS guideline.

28 **Methods:** OVID MEDLINE, All EBM, PsycINFO, EMBASE, and CINAHL were searched from
29 inception until 11 July 2022. Any study with a description of a PCOS MoC was included. Non-
30 evidence-based guidelines, abstracts, study protocols, and clinical trial registrations were excluded. We
31 also excluded MoCs delivered in research settings to minimize care bias. Meta-analysis was not
32 performed due to heterogeneity across MoCs. We describe and evaluate each MoC based on the
33 recommendations made by the international evidence-based guideline for the assessment and
34 management of PCOS.

35 **Results:** Of 3671 articles, six articles describing five MoCs were included in our systematic review.
36 All MoCs described a multidisciplinary approach including an endocrinologist, dietitian,
37 gynaecologist, psychologist, dermatologist, etc. Three MoCs described all aspects of PCOS care
38 aligning with the international guideline recommendations. These include providing education on long-
39 term risks, lifestyle interventions, screening, and management of emotional well-being,
40 cardiometabolic diseases, and dermatological and reproductive elements of PCOS. Three MoCs
41 evaluated patients' and healthcare professionals' satisfaction, with generally positive findings. Only
42 one MoC explored the impact of their service on patients' health outcomes and showed improvement
43 in BMI.

44 **Conclusions:** There is limited literature describing PCOS MoCs in routine practice. Future research
45 should explore developing cost-effective co-created multidisciplinary PCOS MoCs globally. This may
46 be facilitated by the exchange of best practices between institutions that have an established MoC and
47 those who are interested in setting up one.

48 1 Introduction

49 Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies among women of
50 reproductive age with a prevalence of 8-13%, depending on the phenotype and the diagnostic criteria
51 used (1). The diagnostic features of the disease are clinical and/or biochemical hyperandrogenism,
52 oligo/anovulation, and polycystic morphologic appearance of the ovaries (2,3). PCOS was originally
53 perceived as a reproductive disorder. However, mounting evidence suggests that PCOS is also a
54 metabolic condition associated with overweight/obesity (4,5), type 2 diabetes mellitus (T2DM) (6,7),
55 fatty liver disease (8–10), and cardiovascular disease (CVD) (11,12). It also has a significant
56 psychological burden that is more than just a consequence of physical symptoms of PCOS(13–16). We
57 proposed an 'iceberg phenomenon' to highlight the neglected and overlooked impact on various
58 aspects of women and individuals with PCOS's health, alongside potential reproductive dysfunction
59 (17). However, the original figure did not include the emotional wellbeing concerns associated with
60 PCOS. So, we have further adopted this figure to highlight the various additional aspects such as
61 anxiety, depression, eating disorders and body image concerns. (**Figure 1**)

62 Several studies have shown that women and individuals with PCOS often have a significant delay in
63 diagnosis, are dissatisfied with their diagnostic experience, information provision, and the management
64 of their PCOS (18–21). Qualitative research has shown women and individuals with PCOS often felt
65 they were not taken seriously by their doctors (22) with care falling short of their expectations, due to
66 limited evidenced-based treatment options (23). The international PCOS guideline (24) recommends

67 patient-centric models of care (MoC) that meet the needs of women and individuals with PCOS across
68 the complexity of clinical features.

69 An MoC is generally conceptualised as an overarching provision of care that is codesigned with end-
70 users, may be shaped by a theoretical basis, and aligns with evidence-based practice and defined
71 standards (25,26). A holistic, best-practice PCOS MoC would entail access to primary care,
72 endocrinologists, gynaecologists, dermatologists, dieticians, and psychologists as required, to educate
73 women and individuals with PCOS about their condition and its long-term consequences, addressing
74 cardiometabolic, reproductive, and dermatological issues and providing lifestyle interventions,
75 psychological and emotional support (**Figure 2**) (24). In the US and Australia, some MoCs have been
76 implemented aligning with the international guideline. The involvement of a psychologist and
77 cognitive-behavioural therapy in PCOS resulted in greater weight loss, improved quality of life and
78 reduced depression and anxiety (27). However, there is no literature comparing findings across MoCs,
79 to advance best practice that can be shared and adopted in other places where women and individuals
80 with PCOS are managed.

81 **2 Objective**

82 To describe the characteristics of available MoCs for PCOS, and their alignment with international
83 guidelines and evaluation of outcomes.

84 **3 Methods**

85 **3.1 Eligibility criteria, information sources, search strategy**

86 This systematic review was registered on PROSPERO CRD42022346539. Studies describing MoC
87 that have more than one speciality in their PCOS management were identified using a search strategy
88 created using MEDLINE limited to English language and human studies. The search strategy was then
89 adapted to different electronic databases. OVID MEDLINE, All EBM, PsycINFO, EMBASE, and
90 CINAHL were searched from inception until 11 July 2022. We also included articles identified by
91 experts (CT) that might be relevant to the study. A full search strategy can be found in **Supplementary**
92 **1**. Studies were included if they described models of care for PCOS. Any study reported in English
93 with a detailed description of a PCOS MoC was included. Non-evidence-based guidelines, abstracts,
94 study protocols, and clinical trial registrations were excluded. We also excluded MoCs delivered in
95 research settings to minimise care bias. Detailed reasons for exclusion can be found in **Supplementary**
96 **2**.

97 **3.2 Study selection**

98 The process for study selection is summarised in **Figure 3**. Titles and abstracts were independently
99 screened by two reviewers (EM, MD) utilizing Covidence software (Covidence systematic review
100 software, Veritas Health Innovation, Melbourne, Australia). Following title and abstract screening, full
101 texts were obtained and screened by EM and MD against the eligibility criteria. Conflicts were resolved
102 following a discussion between the two reviewers and if needed, by a senior reviewer (PK).

103 **3.3 Data extraction**

104 The data extraction template was developed by the researchers (EM, MD, PK) in partnership with the
105 PCOS GDG members (CT, JB, MT) to ensure relevance. Data extracted included the service name, a
106 detailed description of the MoC and the service, management, and evaluation.

107 3.4 Assessment of risk of bias

108 Risk of bias assessments was done using the Monash Centre for Health Research and Implementation
109 (MCHRI) evidence synthesis critical appraisal templates, adapted from the relevant Cochrane critical
110 appraisal tool(s) for mixed-method studies and cross-sectional studies (28). For each study, external
111 and internal validity were assessed to determine the overall risk of bias for that study.

112 The findings of this review are reported based on the Preferred Reporting Items for Systematic Reviews
113 and Meta-Analyses (PRISMA) guidelines (29). Data are summarised in **Table 1** with narrative
114 synthesis. Meta-analysis was not performed due to heterogeneity across MoCs. We describe and
115 evaluate each MoC based on the recommendations made by the international evidence-based guideline
116 for the assessment and management of PCOS (24).

117 4 Principal Findings

118 3671 articles were identified for title and abstract screening. Of these, 51 articles underwent full-text
119 screening of which six articles describing five MoCs are included in this report (**Figure 3**). Bekx,
120 Connor, and Allen (30) and Geier, Bekx, and Connor (31) (MoC A) described an adolescent PCOS
121 clinic at the American Family Children's Hospital, United States; Boyle et al. (32) (MoC B) described
122 a pilot clinic on Thursday Island, Australia; Torres-Zegarra et al. (33) (MoC C) described a
123 multidisciplinary clinic for PCOS at Children's Hospital Colorado, United States; Tay et al. (34) (MoC
124 D) described the Monash Health state-wide integrated PCOS service, Australia; Patil et al. (35) (MoC
125 E) described an integrated multidisciplinary clinic at Indian Council of Medical Research, India. Two
126 were mixed-methods studies and others were cross-sectional. The objectives of the six articles varied.
127 MoC A, Bekx et al. (30) characterised patients referred to their multidisciplinary clinic, while Geier et
128 al. (31) aimed to examine the impact of MoC A on weight among adolescents with PCOS. Boyle et al.
129 (32) evaluated MoC B based on the fidelity to evidenced-based guideline, barriers and enablers to
130 women and individuals using their service and MoC's ability to meet the needs of women and
131 individuals with PCOS. Torres-Zegarra et al. (33) described the characteristics of patients and pattern
132 of MoC C. Tay et al. (34) evaluated MoC D based on a comprehensive evaluation framework described
133 by Markiewicz and Patrick (36). MoC E described the process of the models of care including
134 retrospective chart analysis of profiles of women attending the clinic (35). A summary of these MoCs
135 is included in **Table 1**.

136 4.1 Characteristics and composition of PCOS MoCs

137 All included MoCs had a multidisciplinary approach, but their compositions varied. MoC A was one
138 of the first published MoCs for women and individuals with PCOS (30,31). Started in 2005, it had a
139 team of two paediatric endocrinologists, a paediatric gynaecologist, a reproductive endocrinologist, a
140 nutritionist, and a psychologist. MoC B, established in 2012, had a general practitioner (GP), women's
141 health nurse, dietician, and women's health worker (32). Set up in 2012, MoC C included paediatric
142 endocrinologists, gynaecologists/adolescent medicine specialists, psychologists, nutritionists, and
143 exercise physiologists (33). A dermatologist was added to the MoC two years later following patient
144 feedback. MoC D, set up in 2017, was an integrated public multidisciplinary service that comprised
145 specialties including endocrinology, dermatology, health coaching, and dietetics (34). Patients were
146 referred to each specialist clinic when required. MoC E described a one-stop MoC involving
147 gynaecologist, infertility specialist, dermatologist, psychiatrist, nutritionist, yoga expert, and
148 counsellor; Women were managed in the clinic on a regular basis (once monthly) (35). Detailed
149 description and characteristics of the MoCs are presented in **Table 1** and **Figure 4**.

150

151 **4.2 Services provided in the MoC.**

152 Three clinics—MoC C, MoC D, and MoC E—reported all aspects of PCOS care in line with the
153 international guideline. All except MoC A had clear information about the criteria they used for
154 diagnosing PCOS.

155 **4.2.1 Cardiometabolic disease**

156 All MoCs described some form of cardiometabolic screening, but content varied. MoC A (30,31)
157 screened for anthropomorphic effects including height, weight, and body mass index (BMI). They also
158 monitored the trends in BMI over time to define successful weight loss or weight gain. 2-hour oral
159 glucose tolerance test, insulin levels and lipid profile were used to screen for dysglycemia,
160 hyperinsulinemia, and dyslipidemia, respectively. MoC B (32) had all screening done by MoC A with
161 addition of glycated Haemoglobin (HbA1c) and blood pressure measurements. MoC C (33) evaluated
162 BMI, blood pressure, lipid profile, and HbA1c. MoC D (34) included screening for long-term
163 complications. However, the individual components of how this was done were not included in the
164 study. MoC E (35) included BMI screening, waist-hip ratio, ultrasound to assess for non-alcoholic fatty
165 liver disease and screening for metabolic syndrome including 2-hour oral glucose tolerance test, insulin
166 and lipid profile.

167

168 **4.2.2 Lifestyle**

169 All MoCs provided lifestyle interventions mostly including goal-settings and education. In MoC A
170 (30,31), the health psychologist focused on lifestyle changes and helped women and individuals with
171 PCOS to identify any barriers that might exist and possible solutions. The nutritionist helped provide
172 education on the role of insulin, meal-planning, goal setting, and exercise. In MoC B (32), patients
173 were encouraged to set their own lifestyle goals which included reduction of portion sizes and
174 increasing daily walks. Patients were then asked to attend a follow-up appointment to evaluate their
175 achievements. MoC C (33) included exercise physiologists and nutritionists who provided lifestyle
176 interventions. Exercise physiologists described each exercise and helped to set activity goals.
177 Nutritionists helped with monitoring weight trends and provided education regarding healthy eating.
178 Further, health nurses provided 30-60 minutes of education for women and individuals with PCOS,
179 covering emotional health, bleeding problems, infertility, endometrial protection, and lifestyle. In MoC
180 D (34), a dietician and/or health coach conducted group sessions discussing the importance of healthy
181 diet and physical activity, personal goal setting, and identification of healthcare barriers. All women,
182 who attended MoC E (35), were advised lifestyle modification with diet and exercise with the help
183 from nutritionist and yoga expert.

184

185 **4.2.3 Dermatology**

186 All MoCs except MoC B (32) described either screening or treatment for dermatological issues
187 associated with PCOS. MoC A (30) described screening for hirsutism and acne. The screening tools
188 used were not specified in the study. MoC C (33) measured hirsutism using the modified Ferriman-

189 Gallwey (mFG) score. Screening for presence and severity of acne was done during physical
190 examination. Presence and absence of acanthosis nigricans, androgenic alopecia, and hidradenitis
191 suppurativa were also noted. As for the treatment, MoC C (33) used spironolactone, topical treatments,
192 antibiotics, and isotretinoin to manage hirsutism and acne. The dermal clinic integrated in MoC D (34)
193 used medical grade laser for hirsutism. MoC E (35) had a dermatologist within the MoC to address
194 acne, oily skin, acanthosis nigricans and/or hirsutism however, no specific treatments were described.

195

196 **4.2.4 Education on long-term risk**

197 MoCs C and D were the only MoCs that reported education on long-term risks (33,34). MoC C (33)
198 set up a group education session, where women and individuals with PCOS were taught by
199 endocrinologists and gynaecologists on the pathophysiology and medical treatment of PCOS. Due to
200 the COVID-19 pandemic, they introduced recorded content for these sessions. MoC D (34) educated
201 women and individuals with PCOS regarding clinical features, diagnosis, complications, and
202 management of PCOS via a group session or printed fact sheets during the first appointment. MoC E
203 (35) counselled women on the condition and the need for integrated multidisciplinary management
204 following the diagnosis of PCOS.

205

206 **4.2.5 Emotional wellbeing and reproductive screening and/or management**

207 Three clinics described provision of screening for emotional wellbeing and reproduction. It was unclear
208 whether MoC A provided emotional and reproductive screening. However, we note that both included
209 health psychologists and a paediatric gynaecologist in the clinic. At MoC B (32), emotional distress
210 screening was undertaken with the Kessler Psychological Distress Scale (37) which is a global measure
211 of distress encompassing anxiety and depression items. A psychologist in MoC C (33) evaluated all
212 patients for mental health symptoms, appetite self-regulation, and emotional eating. In MoC D (34),
213 all women and individuals with PCOS were screened using a modified PCOS questionnaire (PCOSQ)
214 (38) and Hospital Anxiety and Depression Scale (HADS) (39) to evaluate their quality of life and
215 emotional distress, respectively. In MoC B (32), reported infertility treatment by lifestyle intervention,
216 metformin prescription, and/or referral to a specialist. MoC C (33) included screening for endometrial
217 hyperplasia and discussion regarding infertility issues, whereas MoC D (34) included the family
218 planning discussion. Women in MoC E (35) were screened for obvious anxiety and/or depression by
219 counsellors and addressed by psychologist or psychiatrist.

220 **4.3 MoC Evaluation**

221 MoC evaluation data were organised into three categories: patient outcomes, health professional
222 outcomes, and other outcomes. MoCs B (32) and MoC D (34) were the only studies that reported their
223 MoCs evaluation. MoC B evaluated outcomes from all three categories while MoC D only evaluated
224 patient and other outcomes. Evaluation of patient outcomes was available for MoC A which
225 investigated the impact of their service on BMI. No evaluation outcomes were available for MoC C.

226 **4.3.1 Patient health outcomes and satisfaction**

227 MoC A (31) evaluated patients' health outcomes including improvement in body weight seen in 36%
228 (n=13/36). Having access to both psychologist and dietician was superior in improving weight
229 compared to seeing either alone. MoC B (32) conducted semi-structured interviews and focus-groups
230 with women and individuals with PCOS to assess their satisfaction from the clinic. Women and
231 individuals with PCOS found it helpful to have access to this clinic and they found the staff
232 knowledgeable. Patients also found collaboration with a dietician helpful and valuable in goal setting
233 but suggested more tailored plans and ongoing supervision, indicating insufficiency in what was
234 provided. Overall, 80% (n=12/15) of patients in MoC D (34) were satisfied with the service. Further
235 semi-structured interviews with women and individuals with PCOS revealed that MoC D covered their
236 multifaceted needs and was effective in providing care and communication. Women and individuals
237 with PCOS also reported positive impact of this clinic on medical management, symptom severity,
238 their understanding about PCOS, confidence in managing PCOS, and emotional wellbeing.
239 Suggestions from the interviews included improvements in efficiency, patient communication,
240 resource provision, infrastructure, and awareness on the service availability. Patients also suggested
241 more resources to promote self-management. For MoC E (35), telephone feedback was obtained from
242 155 women who attended the clinic. One year following clinic attendance, 83.8% reported adherence
243 to medication, 52.3% and 46.5% adhered to exercise and dietary interventions, respectively. Sixty-
244 eight percent of women were convinced that multidisciplinary clinics were helpful in weight reduction
245 and psychological well being.

246 **4.3.2 Health professional satisfaction**

247 Health professionals' satisfaction was investigated by Boyle et al. (2017) in MoC B (32). A survey
248 among service providers found high levels of job satisfaction and professional investment. The service
249 providers saw absence of a psychologist as a particular problem. The barriers and enablers to clinic
250 sustainability and service delivery were also discussed. Key barriers to sustainability included issues
251 that may arise due to lack of cover during leave, administrative support, funding, high staff turnover,
252 and system issues. The increased demand for the service, although was a strong reason to continue
253 expanding the clinic, was cited as a barrier due to the lack of service providers' availability.

254 **4.4 Risk of bias of included studies.**

255 Five studies were deemed low risk of bias by the reviewers. One study [MoC A (30)] had moderate
256 risk of bias due to inadequate information on case selection. Furthermore, inclusion and exclusion
257 criteria for the study were not described. The detailed risk of bias assessment for each included study
258 is presented in **Supplementary 3**.

259 **5 Comparison with Existing Literature**

260 To date, little progress has been made towards establishing evidence based PCOS MoCs. Existing
261 MoCs vary considerably in breadth of multidisciplinary features with few covering all recommended
262 aspects of care (cardiology, reproduction, dermatology, emotional wellbeing, lifestyle, and long-term
263 risk). Moreover, it is important to note that some of these studies were not designed to evaluate their
264 MoC, which accounted for the lack of details of each reported MoC. Lack of progress could be because
265 such models exist but are not published, health system constraints hinder development (funding, health
266 policy), or there is a lack of know-how about development. Good MoC for PCOS may exist however,
267 without their publication, the opportunity to share best practice is lost. We also noted the lack of

268 systematic reporting and evaluation of MoCs in PCOS, and here we have established a structure for
269 capturing and reporting MoC characteristics to support future work. Future research should concentrate
270 on the evaluation of routine MoC with the focus on patients' experience and satisfaction. This would
271 enable sharing of best practice in the care of women and individuals with PCOS.

272 The lack of progress in MoC evaluation in the literature is surprising considering the high prevalence
273 of PCOS as a chronic condition. A systematic review on chronic disease MoC reported that >90% of
274 their included MoCs (n=75/77) reported positive impact on healthcare practices and outcomes (40).
275 Clearly, there is a need and an apparent benefit from multidisciplinary, dedicated one-stop clinics
276 covering all aspects of PCOS, such as the MoCs by Tay et al. (2021) (34) and Torres-Zegarra et al.
277 (2021) (33). This is also in line with the study by Ismayilova and Yaya (2022), where people expressed
278 the need for more PCOS-centric clinics (20). As management of PCOS is largely individualised due to
279 heterogeneity and a broad range of clinical features, having access to multiple disciplines is important
280 (24). However, our results show that the integration of different disciplines varied considerably; yet
281 four out of the five MoCs showed positive patients' and/or healthcare professionals' satisfaction.

282 Our systematic review showed that none of the peer reviewed MoCs are optimised in line with our
283 suggested MoC structure for women and individuals with PCOS. Despite having all the services for
284 women and individuals with PCOS by Tay et al. (2021) (34), Torres-Zegarra et al. (2021) (33), and
285 Patil et al. (2022) (35), there is currently little evidence on stakeholders' satisfaction of their MoCs. To
286 ensure optimization and sustainability of dedicated MoCs, careful design of components of care is
287 important including a plan for continuous evaluation and monitoring (41). Financial and human
288 resources also play a role in designing such MoC. Despite the high prevalence and long-term
289 consequences of PCOS, as well as the estimated financial impact at \$4.36 billion (42), PCOS receives
290 less than 0.01% of national funding in the US (43). There is a clear need for greater awareness and
291 priority on this condition. This also impacts access to treatment options for PCOS-related symptoms
292 such as expensive laser hair removal and electrolysis for hirsutism (24,42,44). Adequate dermatology
293 management should be provided as hormonal manipulation with contraceptive pills is not always
294 effective and acne can cause significant mental health issues. Women and individuals with PCOS
295 should be educated about sub-fertility due to anovulation and, more importantly, referred to fertility
296 specialists when indicated. As PCOS is also recognized as a metabolic condition, women and
297 individuals with PCOS should be regularly screened for cardiovascular risks and informed of its long-
298 term consequences. Because PCOS is also associated with endometrial cancer, education and public
299 awareness regarding weight loss and progesterone use to reduce endometrial cancer risk is of
300 paramount importance. Emotional wellbeing screening and appropriate referral is also important for
301 women and individuals with PCOS due to high prevalence of anxiety, depression, and reduced quality
302 of life that goes beyond physical manifestations of PCOS. All of these would improve self-management
303 strategies for women and individuals with PCOS coupled with lifestyle interventions that can be
304 provided by healthcare professionals, namely nutritionist, exercise physiologists, and lifestyle coach.
305 Moreover, it is important to ensure race, culture, and tradition are also factored in when designing an
306 MoC as these have been shown to influence the differential services received by women and
307 individuals with PCOS (45–49). This makes it vital to involve women and individuals with PCOS and
308 their families in co-designing services (48).

309 Many studies have shown that women and individuals with PCOS are generally dissatisfied with their
310 diagnosis experience, information provided, and management of their PCOS (18,19,21,22,50). Patient
311 satisfaction is also an important aspect in healthcare as it has been shown to affect clinical outcomes
312 and patient retention. Furthermore, patient satisfaction also affects time and efficacy of healthcare
313 delivery which is often used as a proxy of quality of healthcare (51). In addition, healthcare professional

314 satisfaction is a key to ensure productivity and sustainability of the service (52). In this context,
315 surprisingly few studies focused on PCOS MoC, and most studies did not assess patients' and
316 healthcare professionals' satisfaction. We have described the satisfaction assessment for two MoCs
317 (32,34) with positive results. Our findings are similar to two studies describing an MoC based at the
318 Royal Berkshire Hospital, UK, which were not included in this systematic review due to being
319 published as conference abstracts without details of evaluation methodologies (53). An audit was
320 conducted for their MoC assessing adequacy of investigations and efficacy of treatment for women
321 and individuals with PCOS attending multidisciplinary clinics. Their patient satisfaction survey
322 showed that 62/63 women found the clinic useful and were happy with the results. They also reported
323 high satisfaction and improved clinical outcomes such as weight loss, menstruation patterns, hirsutism,
324 and physical activity levels (53,54). A further seven studies that might include PCOS MoC were also
325 excluded from this systematic review because they were abstracts. Hebbar et al. investigated the
326 prevalence of anxiety and body dysmorphia in women and individuals with PCOS attending PCOS
327 specialist clinics in the UK and India (55). The components of their MoC were not described in the
328 abstract (55). Abudu et al. also studied the patient characteristics and subjective improvements in acne
329 for women and individuals attending multidisciplinary PCOS clinics, without description of specialists
330 in the multidisciplinary team (56). Other excluded three studies described either group counselling,
331 self-management, and/or support services for women and individuals with PCOS (57–59).

332

333 **5.1 Strengths and limitations**

334 The strength of this review includes applying clear definitions of a MoC which enabled the capture of
335 studies aligning with the international guideline. We also established a system to report MoCs; it is
336 important to note that there might be another system that exists for an “optimal MoC”. Our key
337 weakness is related to the limited number of MoCs described internationally, and we note the included
338 MoCs are from two high-income countries—the US and Australia. Therefore, we are unable to
339 generalise our findings to a wider population. Furthermore, due to the design of included studies, not
340 every component of MoCs included are captured in our findings. This does not mean that they did not
341 provide the service. Despite only a small number of included studies, this systematic review provides
342 a structured evaluation of the current MoCs of PCOS internationally and further explores their
343 effectiveness.

344 **6 Conclusion and implications**

345 There is a limited number of models of multidisciplinary care currently available in PCOS, with a
346 scarcity of data, especially in low- and middle-income countries. Good MoCs may exist but without
347 their publications, the opportunities to share best practices are lost. Studies on MoC that evaluated
348 patients' and healthcare professionals' satisfaction were generally positive. Future work focusing on
349 MoC scale-up should include development of a best-practice MoC framework, co-designed with
350 women and individuals affected by PCOS across different countries. Alignment with the updated best
351 practice in the 2023 guideline will be important, with adaptation to the range of health systems and
352 resource settings, alongside a need for ongoing evaluation and sharing of results to further develop
353 the evidence-based on real-world experiences.

354 **7 References**

- 355 1. Yildiz BO, Bozdog G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and
356 cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. *Hum*
357 *Reprod* [Internet]. 2012 [cited 2022 Dec 11];27(10):3067–73. Available from:
358 <https://pubmed.ncbi.nlm.nih.gov/22777527/>
- 359 2. Fauser BCJM, Tarlatzis, Fauser, Chang, Aziz, Legro, et al. Revised 2003 consensus on
360 diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).
361 *Hum Reprod* [Internet]. 2004 Jan [cited 2022 May 1];19(1):41–7. Available from:
362 <https://pubmed.ncbi.nlm.nih.gov/14688154/>
- 363 3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit
364 W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a
365 predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin*
366 *Endocrinol Metab* [Internet]. 2006 [cited 2022 May 1];91(11):4237–45. Available from:
367 <https://pubmed.ncbi.nlm.nih.gov/16940456/>
- 368 4. Barber TM, Franks S. Obesity and polycystic ovary syndrome. *Clin Endocrinol (Oxf)*
369 [Internet]. 2021 Oct 1 [cited 2022 May 14];95(4):531–41. Available from:
370 <https://pubmed.ncbi.nlm.nih.gov/33460482/>
- 371 5. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women
372 with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update*
373 [Internet]. 2012 Nov [cited 2022 May 15];18(6):618–37. Available from:
374 <https://pubmed.ncbi.nlm.nih.gov/22767467/>
- 375 6. Boureaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired
376 fasting glucose among PCOS subjects: results of an 8-year follow-up. *Curr Diab Rep*
377 [Internet]. 2006 Feb [cited 2022 May 1];6(1):77–83. Available from:
378 <https://pubmed.ncbi.nlm.nih.gov/16522285/>
- 379 7. Rubin KH, Glinborg D, Nybo M, Abrahamsen B, Andersen M. Development and Risk
380 Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary
381 Syndrome. *J Clin Endocrinol Metab* [Internet]. 2017 Oct 1 [cited 2022 May 1];102(10):3848–
382 57. Available from: <https://pubmed.ncbi.nlm.nih.gov/28938447/>
- 383 8. Luque-Ramírez M, Mendieta-Azcona C, Álvarez-Blasco F, Escobar-Morreale HF. Androgen
384 excess is associated with the increased carotid intima-media thickness observed in young
385 women with polycystic ovary syndrome. *Hum Reprod* [Internet]. 2007 [cited 2022 May
386 1];22(12):3197–203. Available from: <https://pubmed.ncbi.nlm.nih.gov/17933750/>
- 387 9. Kumarendran B, O'Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ, et al.
388 Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in
389 women: A longitudinal study based on a United Kingdom primary care database. *PLoS Med*
390 [Internet]. 2018 Mar 1 [cited 2022 May 1];15(3). Available from:
391 <https://pubmed.ncbi.nlm.nih.gov/29590099/>
- 392 10. Sarkar M, Terrault N, Chan W, Cedars MI, Huddleston HG, Duwaerts CC, et al. Polycystic
393 Ovary Syndrome (PCOS) Is Associated With NASH Severity and Advanced Fibrosis. *Liver*
394 *Int* [Internet]. 2020 Feb 1 [cited 2022 Jun 5];40(2):355. Available from:
395 [/pmc/articles/PMC6980925/](https://pubmed.ncbi.nlm.nih.gov/33460482/)

- 396 11. Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary
397 syndrome and non-alcoholic fatty liver disease: an update meta-analysis. *Reprod Health*
398 [Internet]. 2018 May 10 [cited 2022 May 1];15(1). Available from:
399 <https://pubmed.ncbi.nlm.nih.gov/29747678/>
- 400 12. Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GGM, et al. Body composition,
401 fat distribution and metabolic characteristics in lean and obese women with polycystic ovary
402 syndrome. *Journal of Endocrinological Investigation* 2004 27:5 [Internet]. 2014 Mar 18 [cited
403 2022 May 1];27(5):424–9. Available from:
404 <https://link.springer.com/article/10.1007/BF03345285>
- 405 13. Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in
406 women with polycystic ovary syndrome: a systematic review and meta-analysis. *Endocrine*
407 [Internet]. 2018 Nov 1 [cited 2022 May 1];62(2):318–25. Available from:
408 <https://pubmed.ncbi.nlm.nih.gov/30066285/>
- 409 14. Yin X, Ji Y, Chan CLW, Chan CHY. The mental health of women with polycystic ovary
410 syndrome: a systematic review and meta-analysis. *Arch Womens Ment Health* [Internet]. 2021
411 Feb 1 [cited 2022 May 1];24(1):11–27. Available from:
412 <https://pubmed.ncbi.nlm.nih.gov/32514730/>
- 413 15. Alur-Gupta S, Chemerinski A, Liu C, Lipson J, Allison K, Sammel MD, et al. Body-image
414 distress is increased in women with polycystic ovary syndrome and mediates depression and
415 anxiety. *Fertil Steril* [Internet]. 2019 Nov 1 [cited 2022 May 1];112(5):930-938.e1. Available
416 from: <https://pubmed.ncbi.nlm.nih.gov/31395311/>
- 417 16. Veltman-verhulst SM, Boivin J, Eijkemans MJC, Fauser BJCM. Emotional distress is a
418 common risk in women with polycystic ovary syndrome: a systematic review and meta-
419 analysis of 28 studies. *Hum Reprod Update* [Internet]. 2012 Nov 1 [cited 2022 Dec
420 18];18(6):638–51. Available from: <https://academic.oup.com/humupd/article/18/6/638/627838>
- 421 17. Kempegowda P, Melson E, Manolopoulos KN, Arlt W, O’Reilly MW. Implicating androgen
422 excess in propagating metabolic disease in polycystic ovary syndrome. *Ther Adv Endocrinol*
423 *Metab* [Internet]. 2020 Jun 24 [cited 2022 May 12];11:2042018820934319. Available from:
424 <http://www.ncbi.nlm.nih.gov/pubmed/32637065>
- 425 18. Hillman SC, Bryce C, Caleyachetty R, Dale J. Women’s experiences of diagnosis and
426 management of polycystic ovary syndrome: a mixed-methods study in general practice. *British*
427 *Journal of General Practice* [Internet]. 2020 May 1 [cited 2022 Nov 24];70(694):e322–9.
428 Available from: <https://bjgp.org/content/70/694/e322>
- 429 19. Hoyos LR, Putra Ma, Armstrong AA, Cheng CY, Riestenberg CK, Schooler TA, et al.
430 Measures of Patient Dissatisfaction With Health Care in Polycystic Ovary Syndrome:
431 Retrospective Analysis. *J Med Internet Res* [Internet]. 2020 Apr 1 [cited 2022 Nov 24];22(4).
432 Available from: <https://pubmed.ncbi.nlm.nih.gov/32314967/>
- 433 20. Ismayilova M, Yaya S. What can be done to improve polycystic ovary syndrome (PCOS)
434 healthcare? Insights from semi-structured interviews with women in Canada. *BMC Womens*
435 *Health* [Internet]. 2022 Dec 1 [cited 2022 Nov 24];22(1). Available from:
436 </pmc/articles/PMC9092874/>

- 437 21. Gibson-Helm M, Tassone EC, Teede HJ, Dokras A, Garad R. The Needs of Women and
438 Healthcare Providers regarding Polycystic Ovary Syndrome Information, Resources, and
439 Education: A Systematic Search and Narrative Review. *Semin Reprod Med* [Internet]. 2018
440 [cited 2022 Dec 18];36(1):35–41. Available from: <https://pubmed.ncbi.nlm.nih.gov/30189449/>
- 441 22. Ismayilova M, Yaya S. “I felt like she didn’t take me seriously”: a multi-methods study
442 examining patient satisfaction and experiences with polycystic ovary syndrome (PCOS) in
443 Canada. *BMC Womens Health* [Internet]. 2022 Dec 1 [cited 2022 Nov 24];22(1):1–21.
444 Available from: <https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-022-01630-3>
445
- 446 23. Copp T, Muscat DM, Hersch J, McCaffery KJ, Doust J, Dokras A, et al. The challenges with
447 managing polycystic ovary syndrome: A qualitative study of women’s and clinicians’
448 experiences. *Patient Educ Couns* [Internet]. 2022 Mar 1 [cited 2022 Nov 24];105(3):719–25.
449 Available from: <https://pubmed.ncbi.nlm.nih.gov/34099308/>
- 450 24. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations
451 from the international evidence-based guideline for the assessment and management of
452 polycystic ovary syndrome. *Hum Reprod* [Internet]. 2018 Sep 1 [cited 2022 Nov
453 6];33(9):1602–18. Available from: <https://pubmed.ncbi.nlm.nih.gov/30052961/>
- 454 25. Davidson P. Beyond the rhetoric: what do we mean by a “model of care”? - PubMed. *Aust J*
455 *Adv Nurs* [Internet]. 2006 May [cited 2022 Dec 4];23(3):47–55. Available from:
456 <https://pubmed.ncbi.nlm.nih.gov/16568879/>
- 457 26. Jones AR, Tay CT, Melder A, Vincent AJ, Teede H. What Are Models of Care? A Systematic
458 Search and Narrative Review to Guide Development of Care Models for Premature Ovarian
459 Insufficiency. *Semin Reprod Med* [Internet]. 2020 Sep 1 [cited 2022 Dec 18];38(4–05):323–
460 30. Available from: <https://pubmed.ncbi.nlm.nih.gov/33684948/>
- 461 27. Cooney LG, Milman LW, Hantsoo L, Kornfield S, Sammel MD, Allison KC, et al. Cognitive-
462 behavioral therapy improves weight loss and quality of life in women with polycystic ovary
463 syndrome: a pilot randomized clinical trial. *Fertil Steril* [Internet]. 2018 Jul 1 [cited 2022 Nov
464 20];110(1):161-171.e1. Available from: <https://pubmed.ncbi.nlm.nih.gov/29908771/>
- 465 28. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al.
466 Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling
467 Studies: The CHARMS Checklist. *PLoS Med* [Internet]. 2014 [cited 2022 Dec
468 18];11(10):e1001744. Available from:
469 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001744>
- 470 29. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
471 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*
472 [Internet]. 2021 Mar 29 [cited 2022 Dec 18];372. Available from:
473 <https://www.bmj.com/content/372/bmj.n71>
- 474 30. Bekx MT, Connor EC, Allen DB. Characteristics of adolescents presenting to a
475 multidisciplinary clinic for polycystic ovarian syndrome. *J Pediatr Adolesc Gynecol* [Internet].
476 2010 Feb [cited 2022 Oct 28];23(1):7–10. Available from:
477 <https://pubmed.ncbi.nlm.nih.gov/19648034/>

- 478 31. Geier LM, Bekx MT, Connor EL. Factors contributing to initial weight loss among
479 adolescents with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol* [Internet]. 2012 Dec
480 [cited 2022 Oct 28];25(6):367–70. Available from:
481 <https://pubmed.ncbi.nlm.nih.gov/23089571/>
- 482 32. Boyle J, Hollands G, Beck S, Hampel G, Wapau H, Arnot M, et al. Process evaluation of a
483 pilot evidence-based Polycystic Ovary Syndrome clinic in the Torres Strait. *Aust J Rural*
484 *Health* [Internet]. 2017 Jun 1 [cited 2022 Oct 28];25(3):175–81. Available from:
485 <https://pubmed.ncbi.nlm.nih.gov/27086940/>
- 486 33. Torres-Zegarra C, Sundararajan D, Benson J, Seagle H, Witten M, Walders-Abramson N, et
487 al. Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing
488 Patterns of a Multidisciplinary Clinic. *J Pediatr Adolesc Gynecol* [Internet]. 2021 Oct 1 [cited
489 2022 Oct 28];34(5):617–25. Available from: <https://pubmed.ncbi.nlm.nih.gov/33794340/>
- 490 34. Tay CT, Pirota S, Teede HJ, Moran LJ, Robinson T, Skouteris H, et al. Polycystic Ovary
491 Syndrome Models of Care: A Review and Qualitative Evaluation of a Guideline-
492 Recommended Integrated Care. *Semin Reprod Med* [Internet]. 2021 Jul 1 [cited 2022 Oct
493 28];39(3–04):133–42. Available from: <https://pubmed.ncbi.nlm.nih.gov/34187051/>
- 494 35. Patil AD, Vaidya RA, Begum S, Chauhan SL, Mukherjee S, Kokate PP, et al. An integrated
495 multidisciplinary model of care for addressing comorbidities beyond reproductive health
496 among women with polycystic ovary syndrome in India. *Indian J Med Res* [Internet]. 2022
497 Sep 1 [cited 2023 Apr 5];156(3):449–58. Available from:
498 <https://pubmed.ncbi.nlm.nih.gov/36588359/>
- 499 36. Markiewicz A, Patrick I. Developing Monitoring and Evaluation Frameworks, by Anne
500 Markiewicz and Ian Patrick. *Canadian Journal of Program Evaluation* [Internet]. 2019 May 24
501 [cited 2023 Jan 3];34(1). Available from:
502 <https://journalhosting.ucalgary.ca/index.php/cjpe/article/view/53169>
- 503 37. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, et al. Short
504 screening scales to monitor population prevalences and trends in non-specific psychological
505 distress. *Psychol Med* [Internet]. 2002 Aug [cited 2022 Dec 18];32(6):959–76. Available from:
506 <https://pubmed.ncbi.nlm.nih.gov/12214795/>
- 507 38. Williams S, Sheffield D, Knibb RC. The Polycystic Ovary Syndrome Quality of Life scale
508 (PCOSQOL): Development and preliminary validation. *Health Psychol Open* [Internet]. 2018
509 Jul 1 [cited 2022 Dec 18];5(2). Available from: [/pmc/articles/PMC6053872/](https://pubmed.ncbi.nlm.nih.gov/33794340/)
- 510 39. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*
511 [Internet]. 1983 [cited 2022 Dec 18];67(6):361–70. Available from:
512 <https://pubmed.ncbi.nlm.nih.gov/6880820/>
- 513 40. Davy C, Bleasel J, Liu H, Tchan M, Ponniah S, Brown A. Effectiveness of chronic care
514 models: Opportunities for improving healthcare practice and health outcomes: A systematic
515 review. *BMC Health Serv Res* [Internet]. 2015 May 10 [cited 2022 Dec 18];15(1):1–11.
516 Available from: [https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-015-](https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-015-0854-8)
517 [0854-8](https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-015-0854-8)

- 518 41. Understanding the process to develop a Model of Care An ACI Framework A practical guide
519 on how to develop a Model of Care at the Agency for Clinical Innovation. 2013 [cited 2022
520 Nov 24]; Available from: www.aci.health.nsw.gov.au
- 521 42. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the
522 polycystic ovary syndrome during the reproductive life span. *J Clin Endocrinol Metab*
523 [Internet]. 2005 Aug [cited 2022 Dec 18];90(8):4650–8. Available from:
524 <https://pubmed.ncbi.nlm.nih.gov/15944216/>
- 525 43. Brakta S, Lizneva D, Mykhalchenko K, Imam A, Walker W, Diamond MP, et al. Perspectives
526 on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded? *J Clin*
527 *Endocrinol Metab* [Internet]. 2017 [cited 2022 Nov 24];102(12):4421–7. Available from:
528 <https://pubmed.ncbi.nlm.nih.gov/29092064/>
- 529 44. Ndefo UA, Eaton A, Green MR. Polycystic Ovary Syndrome: A Review of Treatment Options
530 With a Focus on Pharmacological Approaches. *Pharmacy and Therapeutics* [Internet]. 2013
531 Jun [cited 2022 Nov 24];38(6):336. Available from: [/pmc/articles/PMC3737989/](https://pubmed.ncbi.nlm.nih.gov/24925927/)
- 532 45. Sendur SN, Yildiz BO. Influence of ethnicity on different aspects of polycystic ovary
533 syndrome: a systematic review. *Reprod Biomed Online* [Internet]. 2021 Apr 1 [cited 2022 Dec
534 4];42(4):799–818. Available from:
535 <http://www.rbmojournal.com/article/S1472648320306428/fulltext>
- 536 46. Paradies Y, Ben J, Denson N, Elias A, Priest N, Pieterse A, et al. Racism as a Determinant of
537 Health: A Systematic Review and Meta-Analysis. *PLoS One* [Internet]. 2015 Sep 23 [cited
538 2022 Dec 4];10(9). Available from: [/pmc/articles/PMC4580597/](https://pubmed.ncbi.nlm.nih.gov/26422162/)
- 539 47. Hendley Y, Zhao L, Coverson DL, Din-Dzietham R, Morris A, Quyyumi AA, et al.
540 Differences in Weight Perception Among Blacks and Whites. *J Womens Health* [Internet].
541 2011 Dec 1 [cited 2022 Dec 4];20(12):1805. Available from: [/pmc/articles/PMC3236990/](https://pubmed.ncbi.nlm.nih.gov/21805180/)
- 542 48. Lau GM, Elghobashy M, Thanki M, Ibegbulam S, Latthe P, Gillett CDT, et al. A systematic
543 review of lived experiences of people with polycystic ovary syndrome highlights the need for
544 holistic care and co-creation of educational resources. *Front Endocrinol (Lausanne)* [Internet].
545 2022 Dec 2 [cited 2022 Dec 4];13:2958. Available from:
546 <https://www.frontiersin.org/articles/10.3389/fendo.2022.1064937/full>
- 547 49. PCOS in Women of Color: Its true impact [Internet]. [cited 2022 Dec 4]. Available from:
548 [https://www.medicalnewstoday.com/articles/made-to-feel-invisible-with-an-invisible-illness-](https://www.medicalnewstoday.com/articles/made-to-feel-invisible-with-an-invisible-illness-pcos-and-women-of-color)
549 [pcos-and-women-of-color](https://www.medicalnewstoday.com/articles/made-to-feel-invisible-with-an-invisible-illness-pcos-and-women-of-color)
- 550 50. Gibson-Helm ME, Lucas IM, Boyle JA, Teede HJ. Women’s experiences of polycystic ovary
551 syndrome diagnosis. *Fam Pract* [Internet]. 2014 Oct 1 [cited 2022 Dec 18];31(5):545–9.
552 Available from: <https://pubmed.ncbi.nlm.nih.gov/24925927/>
- 553 51. Prakash B. Patient Satisfaction. *J Cutan Aesthet Surg* [Internet]. 2010 [cited 2023 Jan
554 13];3(3):151. Available from: [/pmc/articles/PMC3047732/](https://pubmed.ncbi.nlm.nih.gov/203047732/)

- 555 52. Dragana Nikic, Mirjana Arandjelovic MN and AS. Job satisfaction in health care workers.
556 Acta Medica Medianae [Internet]. 2008 [cited 2023 Jan 13];47((4)):9–12. Available from:
557 https://www.researchgate.net/publication/26605370_Job_satisfaction_in_health_care_workers
- 558 53. Ghosh D MC& EM. A 2 year audit of the polycystic ovary syndrome (PCOS) clinic at the
559 Royal Berkshire Hospital | BES2005 | 24th Joint Meeting of the British Endocrine Societies |
560 Endocrine Abstracts [Internet]. [cited 2022 Nov 24]. Available from: <https://www.endocrine-abstracts.org/ea/0009/ea0009p79>
561
- 562 54. Eldridge Sarah MC& EM. Audit of the Polycystic Ovary Syndrome (PCOS) Nurse led weight
563 management clinic | SFE BES2007 | Society for Endocrinology BES | Endocrine Abstracts
564 [Internet]. [cited 2022 Nov 24]. Available from: <https://www.endocrine-abstracts.org/ea/0013/ea0013p255>
565
- 566 55. Hebbar M, Shaikh S, Zia N, Sheikh J, Wicks S, Jayaprakash S, et al. PCOS SEVa: High
567 prevalence anxiety and body dysmorphia in women with PCOS attending specialist care in the
568 UK and India. Endocrine Abstracts [Internet]. 2022 May 7 [cited 2023 Jan 13];81. Available
569 from: <https://www.endocrine-abstracts.org/ea/0081/ea0081ep898>
- 570 56. Boya Abudu, Nicole Golbari, Martina Porter RR. Patient characteristics and subjective
571 improvement of acne in a multidisciplinary polycystic ovary syndrome clinic. J Am Acad
572 Dermatol [Internet]. 2019 Oct 1 [cited 2023 Jan 13];81(4):AB99. Available from:
573 <http://www.jaad.org/article/S0190962219313829/fulltext>
- 574 57. Young CC. An Integrated Self-Management Intervention for Adolescents With Polycystic
575 Ovary Syndrome - Full Text View - ClinicalTrials.gov [Internet]. 2018. [cited 2023 Jan 13].
576 Available from: <https://www.clinicaltrials.gov/ct2/show/NCT03600337>
- 577 58. Ansari F, Hamzehgardeshi Z, Elyasi F, Moosazadeh M, Ahmadi I. The effect of motivational
578 interview based on WhatsApp on the psychological domains of quality of life in infertile
579 women with pcos: A randomized clinical trial. European Psychiatry [Internet]. 2021 Apr [cited
580 2023 Jan 13];64(Suppl 1):S789. Available from: </pmc/articles/PMC9480087/?report=abstract>
- 581 59. Brooks MA. Online support services: General well-being in women with polycystic ovarian
582 syndrome as a function of the amount of time and satisfaction with online support services.
583 Dissertation Abstracts International: Section B. 2005;66(5-B):2811.

584

585 **8 Conflict of Interest**

586 This systematic review was conducted as part of the international guideline update for polycystic
587 ovary syndrome (**PROSPERO registration number:** CRD42022346539. **Date registered:** 25 July
588 2022). No conflict of interest for all the authors involved in the manuscript.

589

590 **9 Author Contributions**

591 All authors reviewed and edited the manuscript and approved it for publication (as per ICMJE criteria
592 for authorship). Both EM and MD were involved in all stages of the study and have contributed equally
593 to this work and share first authorship. KM contributed to the design of the study and data analysis.
594 CTT, JB, MT supervised the data extraction and finalised the articles included in the study. Members
595 of the PCOS SEva working group provided substantial contributions to the conception and design of
596 the work and were involved in discussions at all stages of the study. The group included Jameela
597 Sheikh, Meghnaa Hebbar, Halimah Khalil, Kashish Malhotra, Tejal Lathia, Helena K. Gleeson, Lynne
598 Robinson, and Chitra Selvan. AM and HT were involved in scoping the clinical question and eligibility
599 criteria (PICO), overseeing the review methodology in alignment with approved PCOS guideline
600 evidence synthesis processes, and reviewing and editing the manuscript. PK conceptualised the study
601 and supervised all stages of data collection, analysis, interpretation, and write-up of this study.

602 **10 Funding**

603 No funding was obtained for this systematic review. HT and AM are supported by a biomedical
604 research fellowship provided by the National Health and Medical Research Council (NHMRC) of
605 Australia.

606 **11 Acknowledgments**

607 We would like to acknowledge Marie Misso who helped in developing the search strategy.

608 **12 Figures**

609 **Figure 1.** An iceberg phenomenon in polycystic ovary syndrome highlighting the emotional wellbeing
610 concerns associated with PCOS.

611 **Figure 2.** (A) outlines 10 recommendations arranged in alphabetical order. The red arrow is the pointer
612 for the starting point of reading the hexagon at cardiometabolic screening. (B) Detailed description of
613 the best-practice PCOS MoC aligned with the international evidence-based guideline for the
614 assessment and management of polycystic ovary syndrome 2018.

615 **Figure 3:** PRISMA chart describing the selection process for our systematic review.

616 **Figure 4:** Graphical representation of the five models of care for polycystic ovary syndrome included
617 in this systematic review. Green represents the services that were provided in a model of care. Yellow
618 represents that the element of MoC was either not reported or unavailable in their MoC. A to F
619 corresponds to the respective models described in this study.

622 **Table 1.** Description of included studies in this study.

	Bekx 2010	Geier 2012	Boyle 2016	Torres-Zegarra 2021	Tay 2021	Patil 2022
Characteristics and composition of PCOS MoC						
Country of MoC	United States	United States	Australia	United States	Australia	India
Name of the clinic	Adolescent PCOS clinic at the American Family Children's Hospital (MoC A)	Adolescent PCOS clinic at the American Family Children's Hospital (MoC A)	Pilot clinic on Thursday Island, Australia (MoC B)	Multidisciplinary clinic for PCOS at Children's Hospital Colorado (MoC C)	Monash Health state-wide integrated PCOS service (MoC D)	Integrated multidisciplinary PCOS clinic at Indian Council of Medical Research (ICMR)-National Institute for Research in Reproductive and Child Health (MoC E)
Year of MoC initiation	2005	2005	2012	2012	2017	2016
Members of multidisciplinary team	Paediatric endocrinologists (x2) Paediatric gynaecologist (x1) Reproductive endocrinologist (x1) Nutritionist (x1) Health psychologist (x1)	Paediatric endocrinologists (x2) Paediatric gynaecologist (x1) Reproductive endocrinologist (x1) Nutritionist (x1)	General practitioner (x1) Women's health nurse (x1) Dietitian (x1) Women's health worker (x1)	Paediatric Endocrinologist (x1) Gynaecologist (x1) Adolescent Medicine Specialist (x1) Dermatologist (x1) (was added to the MoC in 2014)	Endocrinologist (x1) Dermatologist (x1) Health coach (x1) Dietician (x1)	Gynaecologist (x1) Infertility specialist (x1) Dermatologist (x1) Psychiatrist (x1) Nutritionist (x1) Yoga expert (x1) Counsellor (x1)

		Health psychologist (x1)		Psychologist(x1) Nutritionist (x1) Exercise Physiologists (x1)		
Services provided in the MoC						
Clear diagnosis of PCOS	Unclear	Participants were given a diagnosis of PCOS based on Rotterdam criteria	Evaluated frequency of Rotterdam criteria met	Requirement for a confirmed diagnosis of PCOS prior to the first visit; however, unclear according to which criteria	PCOS diagnosis confirmation; however, unclear according to which criteria	PCOS diagnosis confirmation based on the Rotterdam criteria
Cardiometabolic screening, referral, or management	BMI and BMI trends, 2-h OGTT and insulin levels measured	BMI and BMI trends, 2-h OGTT and insulin levels	BMI and BMI trends, blood pressure, 2-h OGTT and insulin levels, HbA1c and lipid profile	BMI, blood pressure, lipid profile and HbA1c	Included screening for long-term health complications but does not describe the components	BMI, waist-hip ratio, blood pressure, ultrasound for non-alcoholic fatty liver disease, lipid profile, 2-h OGTT
Dermatological screening, referral or management	Hirsutism and acne screening (unspecified screening tool)	Not described	Not described	Hirsutism, acanthosis nigricans and acne screening. Hirsutism with mFG score. Acanthosis and acne were subjective	Medical grade laser for treatment of hirsutism	Acne assessment, Hirsutism with FG score. Dermatologist involved with the management of acne and hirsutism
Education on long-term risk	Not described	Not described	Not described	Group education session on the pathophysiology and medical	Educated attendees regarding the clinical features,	Following diagnosis, women were counselled about the condition and the

				treatment approaches of PCOS. Educational session by a nutritionist and exercise physiologist on lifestyle recommendations. 30-60 minutes of education to attendees, covering emotional health, bleeding problems, infertility, endometrial protection, and lifestyle factors	diagnosis, complications, and management of PCOS via a group session or printed fact sheets during the first appointment.	need for an integrated multidisciplinary management
Emotional wellbeing screening, referral or management	Unclear	Unclear	Emotional distress screening was with the Kessler Psychological Distress Scale (37)	Psychologist evaluated all patients for mental health symptoms, appetite self-regulation, and emotional eating.	screened using modified PCOS questionnaire (PCOSQ) (38) and Hospital Anxiety and Depression Scale (HADS) (39)	One stop included psychiatrist and psychological counselling that included screening for emotional, mental health, and QoL
Reproductive screening, referral or management	Unclear	Unclear	lifestyle intervention, metformin prescription, and/or referral to the specialist	screening for endometrial hyperplasia and discussion regarding future infertility issues	Family planning discussion	Has access to gynaecologist and infertility specialist
Lifestyle referral or management	Psychologist helped attendees identify	Psychologist helped attendees	Patients encouraged to set	Exercise physiologist helped	Dietician and/or health coach	All the women were advised lifestyle

	barriers that might exist and possible solution. Nutritionist helped with education on the role of insulin, meal planning, goal setting, and exercise	identify barriers that might exist and possible solution. Nutritionist helped with education on the role of insulin, meal planning, goal setting, and exercise	own goals including reduction of portion sizes and increasing their walking with follow-up appointments	describe goals for each exercise and set activities and goals at appointments. Nutritionist helped with monitoring weight trends and education regarding healthy eating	conducted lifestyle group sessions discussing the importance of healthy diet and physical activity, personal goal setting, and identification of healthcare barriers	modification with diet and exercise in consultation with a nutritionist and yoga expert. Yoga sessions were held as a group activity on the monthly clinic day and women were taught how to practice the specific asanas at home
Evaluations of MoC						
Health professional satisfaction	No	No	Yes	No	No	No
Patient health outcomes	No	Yes	Not described	No	No	Yes
Patient reported outcomes	No	No	Yes	No	Yes	Yes

623

624 **13 Data Availability Statement**

625 No dataset was generated for this study. The search strategies and risk of bias assessments are included in the supplementary materials.

626 **14 Supplementary Material**

627 Supplementary Material is uploaded separately on submission.